| Prev Close | 577.78 |
| Day Low/High | 565.00 / 581.30 |
| 52 Wk Low/High | 441.00 / 660.00 |
Regeneron Pharmaceuticals, Inc. (REGN)
581.01
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 106.54B |
| Market Cap | 61.56B |
| P/E Ratio | 19.71 |
| Div & Yield | N.A. (N.A) |
Regeneron Pharmaceuticals Ready to Make All-Time Highs
Shares have regained their 50-day moving average and look likely to push higher.
Cramer: Rotations Hit Companies That Don't Deserve It
Case in point: Home Depot and Lowe's.
Cramer: Stop Talking About the 'Market'
It just isn't as useful or descriptive right now.
Cramer: This Is No Country for Old Value
Down-and-out stocks have become toxic.
Cramer: You Need 2 Monday Morning Game Plans
We really want to shake out the weak hands here.
Cramer: Rally Is Earning Some Trust
The market rally broadened out nicely today.
Charting the Biotechs
Time to revisit some stocks now that biotech has cooled.
Regeneron Shows Green Shoots
Clues in the chart point to higher prices to come.
Cramer: Retail Rally Shows the Perils of Being Too Negative
There's a forest fire in the sector.
Regeneron Is Ready to Rally
An upside breakout appears on the horizon.
Regeneron Could Generate More Upside
Dips in the pharma name have been bought, a sign of demand that presents a relatively low-risk buying opportunity.
Regeneron Is Ready to Reanimate: Watch for a Breakout
This stock is testing resistance and could push back up to last year's highs.
Cramer: Don't Give the Fed Credit
Most of the 10 best stocks of the bull market did it their way.
Cramer: When a Trump Tweet Is a Buy Signal
Drug companies are the latest targets/beneficiaries.
Cramer: Money's Being Thrown at Almost Everything in the Market
There are nearly too many surging sectors to count.
Cramer: Buyers for Bristol-Myers Are Few and Far Between
Icahn may have a tough time finding interest in this behemoth.
Amgen Shows a Bullish Breakout
There is more upside to come for this stock.
Bullish Momentum for Regeneron
Volatility has calmed down, and there are bullish signs.
Cramer: Here's the Reason for Allergan's Remarkable Run
Static doesn't work in this industry. Pipelines work.
Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short
The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.
Jim Cramer Sees Buying Opportunities in Praluent Patent Suit
After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.
Use Regeneron's Current Weakness to Go Long
Usually I prefer to buy strength as opposed to buying weakness, but I want to depart from my normal behavior with this biotech.
Prepare for Biotech Action Aplenty Today
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...
Regeneron Cholesterol-Lowering Drug Banned From U.S. Market
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
Cramer: Reviewing S&P's Hit-and-Miss Parade
Even among the losers, buys are scarce.
Ophthtech Shares Plunge as Drug Fails in Late Stage Trial
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
